Provided by Tiger Fintech (Singapore) Pte. Ltd.

SCYNEXIS Inc

0.9320
+0.07378.59%
Post-market: 0.93200.00000.00%19:47 EDT
Volume:215.08K
Turnover:195.83K
Market Cap:35.37M
PE:-1.19
High:0.9643
Open:0.8500
Low:0.8251
Close:0.8583
Loading ...

Company Profile

Company Name:
SCYNEXIS Inc
Exchange:
NASDAQ
Establishment Date:
1999
Employees:
29
Office Location:
1 Evertrust Plaza,13th Floor,Jersey City,New Jersey,United States
Zip Code:
07302-6548
Fax:
- -
Introduction:
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of various fungal infections, including invasive candidiasis, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

Directors

Name
Position
David Angulo
Chief Executive Officer, President and Director
Guy Macdonald
Chairman of the Board, Director
Ann F. Hanham
Director
Armando Anido
Director
David Hastings
Director
Philippe Tinmouth
Director
Steven C. Gilman
Director

Shareholders

Name
Position
David Angulo
Chief Executive Officer, President and Director
Ivor Macleod
Chief Financial Officer
Scott Sukenick
General Counsel